Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: Results from the randomized placebo-controlled FUTURE 2 study

80Citations
Citations of this article
107Readers
Mendeley users who have this article in their library.

Abstract

Objective. To determine the effect of prior tumor necrosis factor inhibitor (TNFi) therapy on secukinumab efficacy in psoriatic arthritis (PsA). Methods. Patients were randomized to secukinumab 300 mg, 150 mg, 75 mg, or placebo. Results. American College of Rheumatology 20 responses at Week 24 with secukinumab 300 mg, 150 mg, 75 mg, and placebo were 58.2%, 63.5%, 36.9%, and 15.9% in TNFi-naive (n =258), and 45.5%, 29.7%, 14.7%, and 14.3% in TNFi-exposed patients (n =139), respectively. Week 52 responses with secukinumab 300 mg, 150 mg, and 75 mg were 68.7%, 79.4%, and 58.5% in TNFi-naive, and 54.5%, 37.8%, and 35.3% in TNFi-exposed patients, respectively. Conclusion. Secukinumab was efficacious in TNFi-naive and TNFi-exposed patients with PsA, with greatest improvements in TNFi-naive patients.

Cite

CITATION STYLE

APA

Kavanaugh, A., McInnes, I. B., Mease, P. J., Hall, S., Chinoy, H., Kivitz, A. J., … Mpofu, S. (2016). Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: Results from the randomized placebo-controlled FUTURE 2 study. Journal of Rheumatology, 43(9), 1713–1717. https://doi.org/10.3899/jrheum.160275

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free